Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | CTSS | P25774 | 1/20 | 0.54 |
| ▸ | CTSK | P43235 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CTSD | P07339 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 5/20 | 0.49 |
| ▸ | HTRA1 | Q92743 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10276787 | 1.00 | CA2 (0.55) | CA2MEN1KMT2ACTSSCTSK | |
| SCHEMBL8769095 | 0.88 | CA2 (0.71) | CA2MEN1KMT2ACTSSCTSK | |
| SCHEMBL27820614 | 0.87 | CA2 (0.54) | CA2MEN1KMT2ACTSSCTSK | |
| SCHEMBL4750042 | 0.86 | CTSS (0.61) | CTSSCTSKBACE1 | |
| SCHEMBL1752665 | 0.84 | CTSS (0.57) | CA2CTSSCTSKBACE1 | |
| SCHEMBL7329532 | 0.84 | BACE1 (0.62) | CA2CTSSCTSKBACE1 | |
| SCHEMBL7341348 | 0.83 | PSMB5 (0.51) | CA2CTSSCTSK | |
| SCHEMBL5363519 | 0.82 | ALDH1A1 (0.53) | CA2MEN1KMT2ACTSSCTSK | |
| SCHEMBL5356158 | 0.82 | ALDH1A1 (0.53) | CA2MEN1KMT2ACTSSCTSK | |
| SCHEMBL7652554 | 0.81 | NPC1 (0.58) | MEN1KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865726-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors | ARRAY BIOPHARMA INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20120178715-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178715-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MTOR, RICTOR, EIF4EBP1 | CA2 4446/4885MEN1 845/4885KMT2A 2140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.